Drug Profile


Alternative Names: ALN-PCS; ALN-PCS01; ALN-PCS02

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antihyperlipidaemics; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 08 Feb 2017 The Supreme Court of British Columbia grants a pre-trial injunction filed against Acuitas Therapeutics by Arbutus Biopharma for Arbutus's lipid nanoparticle (LNP) technology
  • 05 Nov 2014 Alnylam receives patent allowance for RNA interference technology in USA
  • 08 Feb 2013 Alynylam and The Medicines Company form an agreement for the global development and commercialisation of ALN PCS for hypercholesterolaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top